Drug or treatment
Abrocitinib clinical trials
As of November 12, 2026, Find a Trial lists 6 clinical trials of Abrocitinib that are recruiting, at sites in 9 countries (most in United States (5), China (2), Hungary (2)). By phase: Phase 3 (2), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 9Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Abrocitinib for eczema and patchy hair loss in people with Down syndrome | Phase 2 | New York, New York | Recruiting | Nov 21, 2025 |
| Abrocitinib for moderate-to-severe atopic dermatitis after inadequate response to biologics | — | San Diego, California | Recruiting | Mar 27, 2025 |
| Long-term abrocitinib oral suspension treatment for children 2 years and older with moderate-to-severe eczema | Phase 3 | Birmingham, Alabama and 39 other locations | Recruiting | Feb 4, 2025 |
| Abrocitinib treatment for children 6 to under 12 with moderate-to-severe eczema | Phase 3 | Birmingham, Alabama and 46 other locations | Recruiting | Feb 4, 2025 |
| Safety of Abrocitinib in Pregnant Women and Their Babies | — | New York, New York | Recruiting | Feb 10, 2023 |
| Learning about Abrocitinib for treating moderate to severe atopic dermatitis in adults | — | Amiens, Somme and 29 other locations | Recruiting | Jan 19, 2023 |
All recruiting trials (6)
-
Abrocitinib for eczema and patchy hair loss in people with Down syndrome
This trial will test whether taking abrocitinib daily can help improve eczema or patchy hair loss in people with Down syndrome aged 12 and up.
-
Abrocitinib for moderate-to-severe atopic dermatitis after inadequate response to biologics
This study will try abrocitinib in adolescents and adults (≥12 years) with moderate-to-severe atopic dermatitis who didn't respond to or couldn't tolerate up to two biologic treatments to see how it works in routine care.
-
Long-term abrocitinib oral suspension treatment for children 2 years and older with moderate-to-severe eczema
This 24-month trial will try a liquid form of the medicine abrocitinib, with or without topical medicines, in children aged 2 years and older who have moderate-to-severe eczema to see if it is safe and helps their skin over time.
-
Abrocitinib treatment for children 6 to under 12 with moderate-to-severe eczema
We will test whether the medicine abrocitinib helps children aged 6 to under 12 with moderate-to-severe eczema and is safe.
-
Safety of Abrocitinib in Pregnant Women and Their Babies
This study is testing whether the medication abrocitinib is safe for pregnant women and their babies compared to women with similar skin conditions who haven't taken the drug.
-
Learning about Abrocitinib for treating moderate to severe atopic dermatitis in adults
This study is testing if taking Abrocitinib daily can safely help adults with moderate to severe atopic dermatitis feel better over two years.
Quick answers
How many clinical trials of Abrocitinib are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 9 countries. The most sites are in United States (5 trials), China (2 trials), Hungary (2 trials), Japan (2 trials), Mexico (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 3: 2, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.